Drug Combination Details
| General Information of the Combination (ID: C59741) | |||||
|---|---|---|---|---|---|
| Name | Ulinastatin NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | WNT3A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
UTI enhanced the 5-FU sensitivity of HCC cells by attenuating their stemness via inhibiting Wnt/Beta-catenin signaling. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth. J Int Med Res. 2020 Mar;48(3):300060520909776. | |||
